Claims for Patent: 7,387,645

Summary for Patent: 7,387,645

Title:	Cellular therapy to heal vascular tissue
Abstract:	The present invention encompasses methods and apparatus for minimizing the risks inherent in endovascular grafting for blood vessel therapy and repair. The invention involves delivering adult stem cells, embryonic stem cells, progenitor cells, fibroblasts, or smooth muscle cells to the diseased blood vessel.
Inventor(s):	Fernandes; Brian (Roseville, MN), Chu; Jack (Santa Rosa, CA), Ganesan; Prema (San Francisco, CA)
Assignee:	Medtronic Vascular, Inc. (Santa Rosa, CA)
Application Number:	10/423,193
Patent Claims:	1. A method of treating an aneurysm in an individual at the aneurysmal site using self-derived cells, comprising: harvesting smooth muscle cell-containing tissue from the individual wherein said tissue is selected from the group consisting of adipose tissue, bone marrow and peripheral blood; isolating smooth muscle cells from the tissue; delivering the isolated smooth muscle cells directly to the wall of a blood vessel at said aneurysmal site by liquid delivery means wherein said blood vessel wall is repaired and said aneurysm is treated in said individual. 2. The method of claim 1, wherein the harvesting step is accomplished by liposuction, drawing blood, or harvesting bone marrow. 3. The method of claim 1, wherein the smooth muscle cells are isolated by growth in selective medium, by density centrifugation, fluorescence activated cell sorting or by magnetic activated cell sorting. 4. The method of claim 1, wherein the smooth muscle cells are isolated by assaying for smooth muscle cell-specific .alpha. actin, calponin, smooth muscle myosin heavy chain, .beta.-tubulin or vimentin expression. 5. The method of claim 1, further comprising the step of modifying the smooth muscle cells after the isolating step. 6. The method of claim 5, wherein the modifying step is accomplished by genetic engineering. 7. The method of claim 6, wherein the smooth muscle cells are genetically engineered to produce at least one cellular factor selected from the group of collagen I, collagen III, elastin, cytokines, growth factors, metalloproteinase inhibitors, inhibitors of inflammation, vitamin A, vitamin C or angiogenic factors. 8. The method of claim 5, wherein the modifying step is in vitro culture expansion of the smooth muscle cells. 9. The method of claim 1, further comprising the step of combining the smooth muscle cells with scaffolding material after the isolating step. 10. The method of claim 9, wherein the scaffolding material is biodegradable. 11. The method of claim 9, wherein the scaffolding material promotes healing. 12. The method of claim 9, wherein the scaffolding material is a gel. 13. The method of claim 12, wherein the gel is a stimuli-responsive gel. 14. The method of claim 13, wherein the stimuli-responsive gel is biodegradable. 15. The method of claim 1, wherein the delivery means is a catheter, cannula, or microneedle. 16. The method of claim 1, wherein the smooth muscle cells to be delivered further comprise a carrier compound. 17. The method of claim 16, wherein the carrier compound is sterile water, normal saline, or culture medium, with or without bioactive agents. 18. A method of repairing an aneurysm in an individual using self-derived cells, comprising: harvesting smooth muscle cell-containing tissue from the individual wherein said tissue is selected from the group consisting of adipose tissue, bone marrow and peripheral blood; isolating smooth muscle cells from the tissue; delivering the isolated smooth muscle cells directly to the wall of a blood vessel at the aneurysm site by a fluid delivery means wherein the blood vessel wall at said aneurysm site is repaired and said aneurysm is treated in said individual. 19. The method of claim 18, wherein the smooth muscle cells are genetically engineered to produce at least one cellular factor selected from the group of collagen I, collagen III, elastin, cytokines, growth factors, metalloproteinase inhibitors, inflammation inhibitor, vitamin A, vitamin C or angiogenic factors.

Details for Patent 7,387,645

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22